紫杉醇脂质体联合顺铂治疗晚期卵巢癌患者的疗效及血清肿瘤标志物水平分析

doi:10.3760/cma.j.issn.1007-1245.2022.23.002

国际医药卫生导报 ›› 2022, Vol. 28 ›› Issue (23): 3260-.DOI: 10.3760/cma.j.issn.1007-1245.2022.23.002

紫杉醇脂质体联合顺铂治疗晚期卵巢癌患者的疗效及血清肿瘤标志物水平分析

刘锦张敏王卉国晓尹春霞

聊城市第三人民医院妇产科，聊城　252000

收稿日期:2022-08-03 出版日期:2022-12-01 发布日期:2022-12-17
通讯作者: 刘锦，Email：jl15506350166@163.com
基金资助:
山东省医药卫生科技发展计划项目（2018WS436）

Efficacy of paclitaxel liposome combined with cisplatin for patients with advanced ovarian cancer and analysis of serum tumor markers

Liu Jin, Zhang Min, Wang Hui, Guo Xiao, Yin Chunxia

Department of Gynecology and Obstetrics, Liaocheng Third People's Hospital, Liaocheng 252000, China

Received:2022-08-03 Online:2022-12-01 Published:2022-12-17
Contact: Liu Jin, Email: jl15506350166@163.com
Supported by:
Project of Developmental Plan of Science and Technology of Medicine and Health in Shandong (2018WS436)

摘要/Abstract

摘要： 目的　探讨紫杉醇脂质体联合顺铂治疗晚期卵巢癌患者的疗效及血清肿瘤标志物水平。方法　选取2018年12月至2021年12月聊城市第三人民医院收治的82例晚期卵巢癌患者，依照随机数表法分为研究组和对照组，每组41例。研究组年龄（51.85±5.19）岁，对照组年龄（50.89±5.58）岁。对照组采用TP方案（紫杉醇+顺铂），研究组采用紫杉醇脂质体联合顺铂治疗。比较两组患者临床疗效、T细胞亚群水平、血清肿瘤标志物癌胚抗原（CEA）及人附睾分泌蛋白4（HE4）水平和不良反应。采用t检验和χ²检验。结果　研究组客观缓解率高于对照组［73.17%（30/41）比51.22%（21/41），P<0.05］。与治疗前相比，两组治疗后CD3⁺、CD4⁺均呈现升高趋势，且研究组均高于对照组（均P<0.05）。与治疗前相比，两组治疗后CEA、HE4水平均降低，且研究组均低于对照组（均P<0.05）。研究组不良反应发生率低于对照组［7.32%（3/41）比29.27%（12/41），P<0.05］。结论　晚期卵巢癌患者应用紫杉醇脂质体联合顺铂治疗可提高疗效，改善免疫功能，减低患者肿瘤标志物水平以及不良反应。

关键词: 紫杉醇脂质体, 顺铂方案, 静脉给药, 癌胚抗原, 人附睾分泌蛋白4

Abstract: 目的　探讨紫杉醇脂质体联合顺铂治疗晚期卵巢癌患者的疗效及血清肿瘤标志物水平。方法　选取2018年12月至2021年12月聊城市第三人民医院收治的82例晚期卵巢癌患者，依照随机数表法分为研究组和对照组，每组41例。研究组年龄（51.85±5.19）岁，对照组年龄（50.89±5.58）岁。对照组采用TP方案（紫杉醇+顺铂），研究组采用紫杉醇脂质体联合顺铂治疗。比较两组患者临床疗效、T细胞亚群水平、血清肿瘤标志物癌胚抗原（CEA）及人附睾分泌蛋白4（HE4）水平和不良反应。采用t检验和χ²检验。结果　研究组客观缓解率高于对照组［73.17%（30/41）比51.22%（21/41），P<0.05］。与治疗前相比，两组治疗后CD3⁺、CD4⁺均呈现升高趋势，且研究组均高于对照组（均P<0.05）。与治疗前相比，两组治疗后CEA、HE4水平均降低，且研究组均低于对照组（均P<0.05）。研究组不良反应发生率低于对照组［7.32%（3/41）比29.27%（12/41），P<0.05］。结论　晚期卵巢癌患者应用紫杉醇脂质体联合顺铂治疗可提高疗效，改善免疫功能，减低患者肿瘤标志物水平以及不良反应。

Key words: Paclitaxel liposome, , Cisplatin protocol, , Intravenous administration, Carcinoembryonic antigen, Human epididymal secretory protein 4

刘锦张敏王卉国晓尹春霞. 紫杉醇脂质体联合顺铂治疗晚期卵巢癌患者的疗效及血清肿瘤标志物水平分析[J]. 国际医药卫生导报, 2022, 28(23): 3260-.

Liu Jin, Zhang Min, Wang Hui, Guo Xiao, Yin Chunxia. Efficacy of paclitaxel liposome combined with cisplatin for patients with advanced ovarian cancer and analysis of serum tumor markers[J]. International Medicine and Health Guidance News, 2022, 28(23): 3260-.

参考文献

[1] Murakami K, Kotani Y, Shiro R, et al. Endometriosis-associated ovarian cancer occurs early during follow-up of endometrial cysts [J]. Int J Clin Oncol, 2020, 25(1):51-58. DOI: 10.1007/s10147-019-01536-5.
[2] Herrera FG, Irving M, Kandalaft LE, et al. Tackling immunotherapy resistance: Developing rational combinations of immunotherapy and targeted drugs[J]. J Immunother Precis Oncol 2019, 20(8):417-433. DOI: 10.4103/JIPO.JIPO_24_18
[3] Muñoz-Galván S, Carnero A. Targeting cancer stem cells to overcome therapy resistance in ovarian cancer [J]. Cells, 2020, 9(6):1402-1409. DOI: 10.3390/cells9061402.
[4] Ford CE, Werner B, Hacker NF, et al. The untapped potential of ascites in ovarian cancer research and treatment [J]. Br J Cancer, 2020, 123(1):9-16. DOI: 10.1038/s41416-020-0875-x.
[5] 孙庆娥, 黄晓燕, 刘海宁. 腹腔热灌注疗法对上皮性卵巢癌腹腔转移患者治疗效果的影响[J]. 癌症进展, 2019, 17(1): 86-89. DOI: 10.11877/j.issn.1672-1535.2019.17.01.23.
[6] Liu B, An R, Yu J. Efficacy of bevacizumab combined with albumin-bound paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer [J]. J BUON, 2019, 24(6):2303-2309.
[7] 古力米热•布然江,热孜亚•库尔班,艾力克木•阿不都玩克,等. 放疗联合热疗治疗复发性卵巢癌患者的临床疗效及对患者免疫功能的影响[J]. 现代生物医学进展,2019,19(4):714-717. DOI:10.13241/j.cnki.pmb.2019.04.024.
[8] 中国抗癌协会妇科肿瘤专业委员会. 卵巢恶性肿瘤诊断与治疗指南(第四版)[J]. 中国实用妇科与产科杂志,2018,34(7):739-749. DOI:10.19538/j.fk2018070110.
[9] 张贺龙. 实体瘤疗效评价标准及演变[J]. 现代肿瘤医学, 2010, 18(5):3. DOI:10.3969/j.issn.1672-4992.2010.05.01
[10] 周惠人,张雅欣,李玉静. 紫杉醇联合顺铂与多西他赛联合卡铂治疗晚期卵巢癌的临床疗效及安全性对比[J]. 实用癌症杂志,2019,34(11):1888-1890. DOI:10.3969/j.issn.1001-5930.2019.11.041.
[11] Yoshihama T, Fukunaga K, Hirasawa A, et al. GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes [J]. Oncotarget, 2018, 9(51):29789-29800. DOI: 10.18632/oncotarget.25712.
[12] Li L, Zhuang Q, Cao Z, et al. Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: a multi-center, randomized, open-label, phase III trial [J]. Oncol Lett, 2018, 15(3):3646-3652. DOI: 10.3892/ol.2018.7761.
[13] Schwandt A, von Gruenigen VE, Wenham RM, et al. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer [J]. Invest New Drugs, 2014, 32(4):729-738. DOI: 10.1007/s10637-014-0078-5.
[14] Gwin William Rayford, Childs Jennifer, Higgins Doreen. Phase II study of neoadjuvant IGFBP-2 vaccination with neoadjuvant carboplatin and paclitaxel in advanced ovarian cancer[J]. J Clin Dnod, 2019, 36(15):25.
[15] Wong Te Fong AC, Thavasu P, Gagrica S, et al. Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models [J]. Oncotarget, 2017, 8(69):113874-113884. DOI: 10.18632/oncotarget.23022.
[16] J Freitas, M Pinho, S Silva. Gastrointestinal, blood bone marrow, neurological toxicity and hypersensitivity caused by the treatment of ovarium carcinoma with Taxol and Cisplatina[J]. Eur J Cancer, 2019, 20(4):952-958. DOI: 10.1016/S0959-8049(1)82092-X
[17] Li M, Cai J, Han X, et al. Downregulation of circNRIP1 suppresses the paclitaxel resistance of ovarian cancer via regulating the miR-211-5p/HOXC8 axis [J]. Cancer Manag Res, 2020, 12: 9159-9171. DOI: 10.2147/CMAR.S268872.
[18] Yang H, Mao W, Rodriguez-Aguayo C, et al. Correction: paclitaxel sensitivity of ovarian cancer can be enhanced by knocking down pairs of kinases that regulate MAP4 phosphorylation and microtubule stability [J]. Clin Cancer Res, 2020, 26(18):5050. DOI: 10.1158/1078-0432.CCR-20-3198.
[19] Jiang L, Hou R. Tetrandrine reverses paclitaxel resistance in human ovarian cancer via inducing apoptosis, cell cycle arrest through β-catenin pathway [J]. Onco Targets Ther, 2020, 13:3631-3639. DOI: 10.2147/OTT.S235533.
[20] Rebecca Christian Arend, Bradley J. Clinical trial in progress: pivotal study of VB-111 combined with paclitaxel versus Paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).[J]. J Clin Dnod, 2020,38(15):96.
[21] Neumann A . Studies from University College Cork Add New Findings in the Area of Health Insurance (Unwinding the State subsidisation of private health insurance…)[J]. 2014,5(8):85.DOI:http://heise.de/-2302778.
[22] Zhang S, Cheng J, Quan C, et al. circCELSR1 (hsa_circ_0063809) contributes to paclitaxel resistance of ovarian cancer cells by regulating FOXR2 expression via miR-1252 [J]. Mol Ther Nucleic Acids, 2020, 19:718-730. DOI: 10.1016/j.omtn.2019.12.005.
[23] Guo M, Li S, Zhao X, et al. Knockdown of circular RNA Hsa_circ_0000714 can regulate RAB17 by sponging miR-370-3p to reduce paclitaxel resistance of ovarian cancer through CDK6/RB pathway [J]. Onco Targets Ther, 2020, 13: 13211-13224. DOI: 10.2147/OTT.S285153.
[24] 吴超扬,郑崇广,马志红. 顺铂与紫杉醇不同给药方式治疗晚期卵巢癌的疗效对比分析[J]. 国际医药卫生导报,2014,20(7):996-998. DOI:10.3760/cma.j.issn.1007-1245.2014. 07.036.
[25] 卢志文,卢光,黄俭. 紫杉醇联合卡铂化疗治疗卵巢癌的临床观察[J]. 国际医药卫生导报,2011,17(5):578-580. DOI:10.3760/cma.j.issn.1007-1245.2011.05.025.
[26] 谢文阳,熊员焕,郭桃英. miR-574-3p通过下调CBX2增强了卵巢癌A2780细胞对紫杉醇的敏感性[J]. 沈阳药科大学学报,2022,39(8):950-956.
[27] 王立,姜忠于,胡春秀,等. 腹腔灌注贝伐珠单抗联合紫杉醇和铂类化疗对Ⅲb～Ⅳ期卵巢癌患者血清肝细胞生长因子和巨噬细胞移动抑制因子水平的影响[J]. 中国妇幼保健,2022,37(15):2864-2868. DOI:10.19829/j.zgfybj.issn.1001-4411.2022.15.041.
[28] Feng Q, Li X, Sun W, et al. Corrigendum to "Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1" [J]. Biochem Pharmacol, 2021, 193: 114757. DOI: 10.1016/j.bcp.2021.114757.
[29] Zhang J, Guan W, Xu X, et al. A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer [J]. Oncogene, 2021, 40(30):4906-4918. DOI: 10.1038/s41388-021-01891-6.
[30] Wang W, Liu M, Ding B. Comparison of the short-term efficacy and serum markers between lobaplatin/paclitaxel- and carboplatin/paclitaxel-based adjuvant chemotherapy in patient with ovarian cancer [J]. J Clin Pharm Ther, 2021, 46(1):166-172. DOI: 10.1111/jcpt.13276.

紫杉醇脂质体联合顺铂治疗晚期卵巢癌患者的疗效及血清肿瘤标志物水平分析

Efficacy of paclitaxel liposome combined with cisplatin for patients with advanced ovarian cancer and analysis of serum tumor markers

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

[1]	商平平, 于泽, 杨晓平. CST4、CA19-9、CA72-4和CEA联合检验诊断胃癌的价值[J]. 国际医药卫生导报, 2022, 28(5): 715-718.
[2]	史文燕　朱建业　管东东. MRI联合肿瘤标志物在卵巢肿瘤诊断中的应用价值[J]. 国际医药卫生导报, 2022, 28(13): 1778-1783.